Selah Genomics, Ferrer inCode to Offer NGS-Based Cardiovascular Test in US; Mull NGS for Other Assays | GenomeWeb

Selah Genomics, a Greenville, S.C.-based molecular diagnostic and genomics services company, has partnered with Spanish pharmaceutical company Ferrer inCode to commercialize Ferrer inCode's suite of cardiovascular genetic tests in the US.

Selah will first validate Ferrer's next-generation sequencing-based test for sudden cardiac death, SudD inCode, on Illumina's MiSeq system to run out of its CLIA-certified and CAP-accredited laboratory.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.